Develops antibody-based therapeutics for eye diseases.
Jun 2026Revenue $11.5M/yrExpenses $55.9M/yr
No trendCash runway ≈ 2.9 years from Jun 2026
Figures by year
When will Surrozen be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $11.5M and expenses $55.9M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $3.48M | $45.6M | −$42.1M |
| Dec 2024 | $10.7M | $36.2M | −$25.5M |
| Dec 2023 | $0.00 | $45.8M | −$45.8M |
| Dec 2022 | $12.5M | $56.8M | −$44.3M |
| Dec 2021 | $0.00 | $54.4M | −$54.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.